Third Consensus Meeting on Neurocognitive and Functional Endpoints in MPS Clinical Studies - PROJECT SUMMARY The mucopolysaccharidosis (MPS) disorders are a set of heterogeneous progressive, life-limiting disorders with variable multi-system complications, including highly diverse effects on the central nervous system (CNS), ranging from rapid neurocognitive decline, often with intense behavioral dysregulation, to mild memory issues. While there has been an explosion in therapy development for MPSes, the ability to measure a convincing response to therapy is complicated by the variable clinical courses across, and within, phenotypes. Incredibly divergent clinical trial approaches internationally had hindered data comparison and raised questions as to whether methodologies were accurately measuring cognitive and adaptive endpoints. In response, two prior international MPS consensus conferences developed guidance for MPS trial design and implementation, particularly for therapies targeting CNS effects. Given rapid advances in the past four years in knowledge about treatments, disease pathology, and the patient/family experience of MPS disorders, it is critical to update the guidance to keep pace with this surging field. The main objective of the Third Consensus Meeting on Neurocognitive and Functional Endpoints in MPS Clinical Studies is to launch a Delphi consensus process to modernize guidance for MPS clinical studies targeting both the CNS and multi-functional impacts of the disorders. The specific aims are to: 1) Update recommendations for endpoint measurement of CNS impacts of MPS across the globe; 2) Improve representation of the diverse needs of MPS disorders, broadening the set of endpoints to be meaningful for how patients/families feel and function; 3) Mentor trainees/early stage investigators (ESIs) on (i) identifying issues in neurocognitive and other functional endpoints and clinical trial execution, (ii) writing literature review talks for the conference, and (iii) composing a manuscript for peer review. A 2-day, in person meeting with a diverse MPS expert panel (researchers, clinicians, advocates) and mentored participation by trainees/ESIs will develop statements for a virtual Delphi process. The proposal's significance is its emphasis on diversity and global representation of a broader set of functional endpoints for MPS clinical studies. Major outcomes of this conference will be to develop modern recommendations for selection and implementation of endpoints that are clinically meaningful to patients/families across the globe, and to enhance career development for trainees/ESIs. This proposal's health relatedness is its potential to guide investigators and industry in trial designs that reliably evaluate CNS response to therapy. The ultimate goal is to accelerate the success of clinical programs for new therapies, and inclusive treatment targets, to improve the lived experience of people touched by MPS.
